Study #2023-0976
A phase IIa, open-label, multiple ascending dose confirmation study of the safety and tolerability of intravenous brincidofovir in subjects with adenovirus infection or cytomegalovirus infection
MD Anderson Study Status
Enrolling
Treatment Agent
BCV
Description
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Adenovirus Infections, Cytomegalovirus Infection
Study phase:
Phase II
Physician name:
Fareed Khawaja
Department:
Infectious Diseases
For general questions about clinical trials:
1-888-356-1897
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.